Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
Phase 2
Terminated
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Drug: LenalidomideDrug: FludarabineDrug: RituximabProcedure: Stem Cell TransplantationDrug: ThymoglobulinDrug: BendamustineDrug: Allopurinol
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT00899431
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma
Phase 1
Terminated
- Conditions
- GlioblastomaCNS DiseaseBrain Diseases
- Interventions
- First Posted Date
- 2009-05-11
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00895960
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Study of Erlotinib in Combination With Bortezomib
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2015-07-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00895687
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Erlotinib in Combination With Dasatinib
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2015-07-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT00895128
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Erlotinib in Combination With Cetuximab
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2015-07-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT00895362
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Caregiver Assessments of the Quality of Home Hospice Care
Terminated
- Conditions
- Advanced Cancer
- Interventions
- Behavioral: Phone Interview/Questionnaire
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 74
- Registration Number
- NCT00895024
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
PR1 Vaccination in Myelodysplastic Syndrome (MDS)
Phase 2
Terminated
- Conditions
- LeukemiaMyelodysplastic Syndrome
- Interventions
- Biological: PR-1 vaccine
- First Posted Date
- 2009-05-06
- Last Posted Date
- 2012-07-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT00893997
- Locations
- 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States
Acupuncture for Chemo-Induced Peripheral Neuropathy
Phase 2
Completed
- Conditions
- MyelomaLymphomaPeripheral Neuropathy
- Interventions
- Other: Acupuncture
- First Posted Date
- 2009-05-01
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00891618
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage
Phase 2
Completed
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2012-02-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 90
- Registration Number
- NCT00890656
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 187
- Registration Number
- NCT00887068
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath